Following on from information provided to NICE by the company in April 2018 the appraisal of Osteoarthritis – naproxcinod [ID417] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 417 |
| Referral date | 01 November 2010 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2018 the appraisal of Osteoarthritis – naproxcinod [ID417] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 27 May 2011 |
The Institute has been informed by the manufacturer that it has withdrawn its application for a centralised marketing authorisation for naproxcinod. Further information NICE has therefore decided to suspend this appraisal on its current work programme for the time being. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual